Press Releases NervGen Pharma Corp.

Equities

NGEN

CA64082X2032

Market Closed - Toronto S.E. Other stock markets 01:29:59 15/05/2024 am IST			5-day change	1st Jan Change
2.11 ^CAD	+0.48%		+4.46%	-21.85%

17/04	NervGen Reports FY 2023 Net Loss of $0.38 Per Share, Provides Operations Update	MT
17/04	NervGen Pharma Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

NervGen Files Management Information Circular and Announces Board of Directors Transition	07/05	NE
NervGen Pharma : Notice of Meeting and Management Proxy Circular	07/05	PU
NervGen Engages Russo Partners LLC to Provide Public Relations Services	25/04	NE
NervGen Pharma Reports 2023 Year-End Financial Results and Operational Updates	17/04	NE
Non-Opioid Revolution: Beacons of Hope in Opioid Crisis and a $50 Million Spin-Off	09/04	AQ
NervGen Completes $23 Million Bought Deal Financing	28/03	NE
Canadian Investment Regulatory Organization Trade Resumption - NGEN	22/03	AQ
NERVGEN ANNOUNCES $20 MILLION BOUGHT DEAL OFFERING	22/03	AQ
Canadian Investment Regulatory Organization Trading Halt - NGEN	22/03	AQ
NervGen Pharma Recognized as a Top 50 TSX Venture Exchange Company	21/02	NE
NervGen Pharma Grants Stock Options	21/02	NE
NervGen Pharma on Track to Complete Enrollment, Deliver Data Readout in Phase 1b/2a Clinical Trial for NVG-291 in Spinal Cord Injury	15/02	NE
NervGen Pharma Reports Q3 2023 Financial Results and Operational Updates	09/11	NE
Neuroscientist and NervGen Pharma Scientific Founder, Dr. Jerry Silver, Interviewed on 'Remarkable People' Podcast Hosted by Tech Luminary Guy Kawasaki	08/11	NE
NervGen Pharma Receives Fast Track Designation for NVG-291 for the Treatment of Individuals with Spinal Cord Injury	23/23/23	NE
NervGen Pharma Appoints John Ruffolo to Board of Directors	17/23/17	NE
NervGen Pharma Announces First Subject Dosed in Landmark Phase 1b/2a Clinical Trial for NVG-291 in Spinal Cord Injury	25/23/25	NE
NervGen Pharma to Present at 2023 International Spinal Research Trust Network Meeting	12/23/12	AQ
NervGen Pharma to Present on Its Drug Candidate NVG-291 and Spinal Cord Injury at the H.C. Wainwright 25th Annual Global Investment Conference	06/23/06	AQ
NervGen Pharma to Present on Its Drug Candidate NVG-291 and Spinal Cord Injury at Investor Conference	23/23/23	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases NervGen Pharma Corp.

Equities

NGEN

CA64082X2032

Press Releases

Filters